XPS™ to Switzerland

The University Hospital in Lausanne CHUV, Switzerland has decided to acquire the Xvivo Perfusion system, XPS™. This is the first XPS™ to a Swiss hospital. It is estimated that delivery and installation of the XPS™ will take place in March 2016.

The XPS™ is the only system on the market for Ex Vivo Lung Perfusion (EVLP) that is approved on all major markets, including US approval by the FDA. The XPS™ system gives the user the flexibility to perform evaluation of lungs for transplantation using a standardized and simplified procedure. The XPS™ has achieved good clinical results when used at leading clinics in the USA and Europe. In Europe, five clinics will have the XPS™-system, whereof one clinic in Switzerland..

“We are very pleased that the clinic in Lausanne, which is one of the most important clinics in Switzerland, now starts to use XPS™ to facilitate EVLP," says Magnus Nilsson, CEO of XVIVO Perfusion.

January 29, 2016
Gothenburg
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information was submitted for publication on January 29, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.